Response

Affiliations

¹ Affiliations of authors: Université de Versailles St-Quentin, EA 4340, F-92104 Boulogne-Billancourt, France (PS); AP-HP, Hôpital Ambroise Paré, Service de Dermatologie Générale et Oncologique, F-92104 Boulogne-Billancourt, France (PS); Université de Versailles St-Quentin, UMR-S 1168, Saint Quentin-en-Yvelines, France (PA); INSERM, U1168 F-94807, Villejuif, France (PA); AP-HP, Hôpital Ambroise Paré, Unité de recherche clinique et département de santé Publique, F-92104 Boulogne-Billancourt, France (PA); Strathclyde Institute for Global Public Health at iPRI, F-69006 Lyon, France (MB); International Prevention Research Institute (iPRI), F-69006 Lyon, France (MB). philippe.saiag@uvsq.fr.
² Affiliations of authors: Université de Versailles St-Quentin, EA 4340, F-92104 Boulogne-Billancourt, France (PS); AP-HP, Hôpital Ambroise Paré, Service de Dermatologie Générale et Oncologique, F-92104 Boulogne-Billancourt, France (PS); Université de Versailles St-Quentin, UMR-S 1168, Saint Quentin-en-Yvelines, France (PA); INSERM, U1168 F-94807, Villejuif, France (PA); AP-HP, Hôpital Ambroise Paré, Unité de recherche clinique et département de santé Publique, F-92104 Boulogne-Billancourt, France (PA); Strathclyde Institute for Global Public Health at iPRI, F-69006 Lyon, France (MB); International Prevention Research Institute (iPRI), F-69006 Lyon, France (MB).

Free article

Comment

Philippe Saiag et al. J Natl Cancer Inst. 2016.

Free article

. 2016 Feb 23;108(4):djw015.

doi: 10.1093/jnci/djw015. Print 2016 Apr.

¹ Affiliations of authors: Université de Versailles St-Quentin, EA 4340, F-92104 Boulogne-Billancourt, France (PS); AP-HP, Hôpital Ambroise Paré, Service de Dermatologie Générale et Oncologique, F-92104 Boulogne-Billancourt, France (PS); Université de Versailles St-Quentin, UMR-S 1168, Saint Quentin-en-Yvelines, France (PA); INSERM, U1168 F-94807, Villejuif, France (PA); AP-HP, Hôpital Ambroise Paré, Unité de recherche clinique et département de santé Publique, F-92104 Boulogne-Billancourt, France (PA); Strathclyde Institute for Global Public Health at iPRI, F-69006 Lyon, France (MB); International Prevention Research Institute (iPRI), F-69006 Lyon, France (MB). philippe.saiag@uvsq.fr.
² Affiliations of authors: Université de Versailles St-Quentin, EA 4340, F-92104 Boulogne-Billancourt, France (PS); AP-HP, Hôpital Ambroise Paré, Service de Dermatologie Générale et Oncologique, F-92104 Boulogne-Billancourt, France (PS); Université de Versailles St-Quentin, UMR-S 1168, Saint Quentin-en-Yvelines, France (PA); INSERM, U1168 F-94807, Villejuif, France (PA); AP-HP, Hôpital Ambroise Paré, Unité de recherche clinique et département de santé Publique, F-92104 Boulogne-Billancourt, France (PA); Strathclyde Institute for Global Public Health at iPRI, F-69006 Lyon, France (MB); International Prevention Research Institute (iPRI), F-69006 Lyon, France (MB).

No abstract available

Comment on

RE: Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients.
Raimondi S, Johansson H, Gandini S. Raimondi S, et al. J Natl Cancer Inst. 2016 Apr;108(4):djw014. doi: 10.1093/jnci/djw014. J Natl Cancer Inst. 2016. PMID: 27092382 No abstract available.